{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:09:10Z","timestamp":1787162950006,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.leukres.2013.09.002","type":"journal-article","created":{"date-parts":[[2013,9,8]],"date-time":"2013-09-08T09:47:47Z","timestamp":1378633667000},"page":"1622-1627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A phase I study of decitabine and rapamycin in relapsed\/refractory AML"],"prefix":"10.1016","volume":"37","author":[{"given":"Jane L.","family":"Liesveld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Ifthikharuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Mulford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Bechelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Minhajuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Gordon L.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.09.002_bib0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/157488706776876445","article-title":"Treatment of relapsed acute myelogenous leukemia","volume":"1","author":"Kell","year":"2006","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.leukres.2013.09.002_bib0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-0609.2011.01703.x","article-title":"Cytoreductive treatment with clofarabine\/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome","volume":"88","author":"Buchholz","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2013.09.002_bib0015","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1158\/0008-5472.CAN-05-2385","article-title":"DNA methylation changes after 5-aza-2\u2032-deoxycytidine therapy in patients with leukemia","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2013.09.002_bib0020","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.09.002_bib0025","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.09.002_bib0030","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine","volume":"107","author":"Blum","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2013.09.002_bib0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00277-012-1607-y","article-title":"Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)","volume":"92","author":"Ganguly","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2013.09.002_bib0040","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1182\/blood-2012-03-413898","article-title":"Clinical and pharmacodynamics activity of bortezomib and decitabine in acute myeloid leukemia","volume":"119","author":"Blum","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.002_bib0045","first-page":"911","article-title":"Oncogenic PI3K and its role in cancer","volume":"20","author":"Samuels","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.leukres.2013.09.002_bib0050","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.leu.2402874","article-title":"Constitutive phosphorylation of Akt\/PKB protein in acute myeloid leukemia: its significance as a prognostic variable","volume":"17","author":"Min","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.09.002_bib0055","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1038\/onc.2008.40","article-title":"Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells","volume":"27","author":"Horn","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2013.09.002_bib0060","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2174\/092986707781368423","article-title":"Targeting the phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside","volume":"14","author":"Martinellii","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.leukres.2013.09.002_bib0065","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2008.144","article-title":"PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML","volume":"22","author":"Park","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.09.002_bib0070","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/1078-0432.CCR-09-0842","article-title":"A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia","volume":"15","author":"Perl","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2013.09.002_bib0075","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","article-title":"Antileukemic activity of rapamycin in acute myeloid leukemia","volume":"105","author":"Recher","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.002_bib0080","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/leu.2008.243","article-title":"Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells","volume":"22","author":"Nishioka","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.09.002_bib0085","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1471-2407-8-163","article-title":"Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma","volume":"8","author":"Chakraborty","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2013.09.002_bib0090","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.leukres.2009.01.041","article-title":"Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia","volume":"33","author":"Xu","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.09.002_bib0095","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1002\/cncr.27429","article-title":"Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients","volume":"118","author":"Faderl","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.09.002_bib0100","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.002_bib0105","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Chesson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.09.002_bib0110","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1080\/10428190701471981","article-title":"Decitabine and its role in the treatment of hematopoietic malignancies","volume":"48","author":"Plimack","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2013.09.002_bib0115","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","article-title":"Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia","volume":"25","author":"Blum","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.09.002_bib0120","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2002-11-3429","article-title":"Survival of acute myeloid leukemia cells requires PI3 kinase activation","volume":"102","author":"Xu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.002_bib0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/leu.2008.246","article-title":"Targeting the leukemic stem cell: the Holy Grail of leukemia therapy","volume":"23","author":"Misaghian","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.09.002_bib0130","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2007-03-080796","article-title":"Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase\/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways","volume":"111","author":"Tamburini","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.002_bib0135","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1432-2277.2005.00134.x","article-title":"Gastrointestinal complications in renal transplant recipients","volume":"18","author":"Ponticelli","year":"2005","journal-title":"Transpl Int"},{"key":"10.1016\/j.leukres.2013.09.002_bib0140","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/leu.2011.339","article-title":"The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia","volume":"26","author":"Willems","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.09.002_bib0145","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1158\/1078-0432.CCR-10-2285","article-title":"Dual mTORC2\/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors","volume":"17","author":"Altman","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2013.09.002_bib0150","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1158\/1078-0432.CCR-10-1102","article-title":"Dual inhibition of PI3K and mTORC1\/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia","volume":"16","author":"Chapuis","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2013.09.002_bib0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory effect of 5-azacytidine (5-azaDc): potential role in the transplantation setting","volume":"115","author":"Sanchez-Abarca","year":"2010","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613003196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613003196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T04:26:53Z","timestamp":1539404813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613003196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0145212613003196"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.09.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study of decitabine and rapamycin in relapsed\/refractory AML","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}